T. Fujita et al., Transactivation of core binding factor alpha 1 as a basic mechanism to trigger parathyroid hormone-induced osteogenesis, JPN J PHARM, 86(4), 2001, pp. 405-416
During 28-day culture of bone marrow- and calvaria-derived osteoblasts, the
constant presence of parathyroid hormone (PTH)(1-34) retarded differentiat
ion and nodule formation (NF) in a dose-dependent fashion (C-phase). In con
trast, addition of PTH(1-34) in late stage cultures (from day 10 to 21) acc
elerated NF (A-phase). The stable production of such an A-phase allowed us
to study the mechanism of bone anabolic action of PTH(1-34). Subcellular lo
calization studies of core binding factor alpha 1 (Cbfa 1) and reporter ass
ays provided the results indicating that in the A-phase, PTH(1-34) triggers
its bone anabolic action via enhancement of Cbfa1 transactivation. RT-PCR
and Northern blot analyses revealed that alkaline phosphatase, osteocalcin
and bone sialoprotein expression decreased in the C-phase and increased in
the A-phase; however, expression of other bone proteins (Cbfa1, PTH/PTH-rel
ated peptide-receptor, osteopontin, collagen I alpha1, collagen I alpha2, v
itamin K-dependent gamma -glutamyl carboxylase) did not change in a phase t
ransition-related manner. Ovariectomized osteopenic mice, treated with PTH(
1-34) (4 and 40 mug/kg, s.c., every other day, 4 or 6 weeks), recovered los
t bone, displayed elevated nuclear localization of Cbfa1 in tibiae without
alteration of its cytosolic level and exhibited upregulation of expressions
of the same set of proteins (alkaline phosphatase, osteocalcin and bone si
aloprotein) in femora. These results obtained by a concerted study in vitro
and in vivo suggest that PTH triggers its osteogenic action via promotion
of the transactivation of Cbfa1.